Roche Holding AG (ROP.SW) — the peer cohort

As of 2026-11-10 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Roche Holding AG ranks 16 of 16 in its cohort on the Closelooknet composite (56/100) — the cohort is led by Halozyme Therapeutics Inc at 70/100.

Name	Composite	Momentum	Quality	Valuation	Signal	Off 52w high
ROP.SW Roche Holding AG	56	83	84	51	ok	1%
HALO Halozyme Therapeutics Inc	70	76	94	36	info	23.1%
ARGX.BR Argen-X	65	85	75	28	ok	6.6%
ONC BeOne Medicines AG	65	91	64	29	ok	0.2%
ANN.AU Ansell Ltd	64	97	48	50	ok	0.9%
LLY Eli Lilly and Company	64	91	90	22	bull	2.8%
ROVI.MC Laboratorios Farmaceuticos ROVI	64	61	77	46	info	18.6%
REGN Regeneron Pharmaceuticals Inc	64	84	72	45	bull	7.2%
UCB.BR UCB SA	64	77	71	41	info	2.2%
ARGX argenx NV ADR	63	79	74	27	ok	9.4%
ORNAV.HE Orion Oyj A	63	94	84	29	ok	1.4%
ORNBV.HE Orion Oyj B	63	94	84	29	ok	1.4%
SAN.PA Sanofi SA	63	75	69	63	bull	0.7%
DXCM DexCom Inc	62	67	79	34	watch	12.4%
HQY HealthEquity Inc	62	75	69	40	ok	6.1%
MEDP Medpace Holdings Inc	62	90	75	25	ok	4.2%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-10

Quick answers

Who are Roche Holding AG's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), BeOne Medicines AG (ONC), Ansell Ltd (ANN.AU), Eli Lilly and Company (LLY), Laboratorios Farmaceuticos ROVI (ROVI.MC), Regeneron Pharmaceuticals Inc (REGN), UCB SA (UCB.BR) and others, as of 2026-11-10.

How does ROP.SW score against its peers?

Roche Holding AG's composite reads 56/100, ranking 16 of 16 in its cohort as of 2026-11-10; the cohort's highest composite is Halozyme Therapeutics Inc at 70/100. Closelooknet scores are research diary readings, not ratings or advice.